CN114395041A - Method for preparing anti-IL-12 and/or IL-23 monoclonal antibody - Google Patents
Method for preparing anti-IL-12 and/or IL-23 monoclonal antibody Download PDFInfo
- Publication number
- CN114395041A CN114395041A CN202210109484.8A CN202210109484A CN114395041A CN 114395041 A CN114395041 A CN 114395041A CN 202210109484 A CN202210109484 A CN 202210109484A CN 114395041 A CN114395041 A CN 114395041A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- cell
- cells
- ser
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 108010065637 Interleukin-23 Proteins 0.000 title claims abstract description 54
- 102000013264 Interleukin-23 Human genes 0.000 title claims abstract description 54
- 210000004027 cell Anatomy 0.000 claims description 127
- 108010065805 Interleukin-12 Proteins 0.000 claims description 60
- 102000013462 Interleukin-12 Human genes 0.000 claims description 60
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 50
- 239000013604 expression vector Substances 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 31
- 230000027455 binding Effects 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 24
- 238000003209 gene knockout Methods 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 101150074355 GS gene Proteins 0.000 claims description 21
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims description 18
- 201000004681 Psoriasis Diseases 0.000 claims description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 18
- 229930006000 Sucrose Natural products 0.000 claims description 18
- 239000005720 sucrose Substances 0.000 claims description 18
- 208000011231 Crohn disease Diseases 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 13
- 238000003259 recombinant expression Methods 0.000 claims description 13
- 101150074155 DHFR gene Proteins 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 229960002885 histidine Drugs 0.000 claims description 12
- 229920000136 polysorbate Polymers 0.000 claims description 12
- 229950008882 polysorbate Drugs 0.000 claims description 12
- 238000010367 cloning Methods 0.000 claims description 11
- 238000005516 engineering process Methods 0.000 claims description 11
- 108091026890 Coding region Proteins 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 10
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 229960004452 methionine Drugs 0.000 claims description 10
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 9
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 9
- 229930195722 L-methionine Natural products 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 9
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 8
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 8
- 150000001413 amino acids Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 229940068968 polysorbate 80 Drugs 0.000 claims description 6
- 238000003306 harvesting Methods 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 108091033409 CRISPR Proteins 0.000 claims description 4
- 238000010354 CRISPR gene editing Methods 0.000 claims description 4
- 238000010353 genetic engineering Methods 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims 1
- 108020001096 dihydrofolate reductase Proteins 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract description 13
- 238000012216 screening Methods 0.000 abstract description 13
- 229940117681 interleukin-12 Drugs 0.000 description 58
- 229940124829 interleukin-23 Drugs 0.000 description 47
- 239000013612 plasmid Substances 0.000 description 40
- 239000002609 medium Substances 0.000 description 31
- 108020002326 glutamine synthetase Proteins 0.000 description 24
- 102000005396 glutamine synthetase Human genes 0.000 description 23
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 239000000047 product Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 102000008070 Interferon-gamma Human genes 0.000 description 15
- 108010074328 Interferon-gamma Proteins 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 229960003130 interferon gamma Drugs 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 11
- 108010022394 Threonine synthase Proteins 0.000 description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 102000004419 dihydrofolate reductase Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229960000485 methotrexate Drugs 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 5
- 108010092854 aspartyllysine Proteins 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 4
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 3
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 3
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 3
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 3
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 3
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 3
- LMKKMCGTDANZTR-BZSNNMDCSA-N Tyr-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LMKKMCGTDANZTR-BZSNNMDCSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 108010087924 alanylproline Proteins 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000012930 cell culture fluid Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108010031719 prolyl-serine Proteins 0.000 description 3
- 108010029020 prolylglycine Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 2
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 2
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 2
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 2
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 2
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- CLPQUWHBWXFJOX-BQBZGAKWSA-N Gln-Gly-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O CLPQUWHBWXFJOX-BQBZGAKWSA-N 0.000 description 2
- LVRKAFPPFJRIOF-GARJFASQSA-N Gln-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N LVRKAFPPFJRIOF-GARJFASQSA-N 0.000 description 2
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 2
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 2
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 2
- ZOTGXWMKUFSKEU-QXEWZRGKSA-N Gly-Ile-Met Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(O)=O ZOTGXWMKUFSKEU-QXEWZRGKSA-N 0.000 description 2
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 2
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 2
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- CWJQMCPYXNVMBS-STECZYCISA-N Ile-Arg-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N CWJQMCPYXNVMBS-STECZYCISA-N 0.000 description 2
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 2
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- -1 L-methionine sulfone imine Chemical class 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 2
- GBDMISNMNXVTNV-XIRDDKMYSA-N Leu-Asp-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O GBDMISNMNXVTNV-XIRDDKMYSA-N 0.000 description 2
- YSKSXVKQLLBVEX-SZMVWBNQSA-N Leu-Gln-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 YSKSXVKQLLBVEX-SZMVWBNQSA-N 0.000 description 2
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 2
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 2
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 2
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 2
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 2
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 description 2
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 2
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 2
- GHQFLTYXGUETFD-UFYCRDLUSA-N Met-Tyr-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N GHQFLTYXGUETFD-UFYCRDLUSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 2
- YFXXRYFWJFQAFW-JHYOHUSXSA-N Phe-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YFXXRYFWJFQAFW-JHYOHUSXSA-N 0.000 description 2
- ZVJGAXNBBKPYOE-HKUYNNGSSA-N Phe-Trp-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 ZVJGAXNBBKPYOE-HKUYNNGSSA-N 0.000 description 2
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 2
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 2
- XWCYBVBLJRWOFR-WDSKDSINSA-N Ser-Gln-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O XWCYBVBLJRWOFR-WDSKDSINSA-N 0.000 description 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 2
- CKDXFSPMIDSMGV-GUBZILKMSA-N Ser-Pro-Val Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O CKDXFSPMIDSMGV-GUBZILKMSA-N 0.000 description 2
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 2
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 2
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 2
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 2
- UJRIVCPPPMYCNA-HOCLYGCPSA-N Trp-Leu-Gly Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N UJRIVCPPPMYCNA-HOCLYGCPSA-N 0.000 description 2
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 2
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 2
- MTEQZJFSEMXXRK-CFMVVWHZSA-N Tyr-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N MTEQZJFSEMXXRK-CFMVVWHZSA-N 0.000 description 2
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 2
- VPEFOFYNHBWFNQ-UFYCRDLUSA-N Tyr-Pro-Tyr Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 VPEFOFYNHBWFNQ-UFYCRDLUSA-N 0.000 description 2
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 2
- USXYVSTVPHELAF-RCWTZXSCSA-N Val-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](C(C)C)N)O USXYVSTVPHELAF-RCWTZXSCSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 108010084389 glycyltryptophan Proteins 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- WCBVQNZTOKJWJS-ACZMJKKPSA-N Ala-Cys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O WCBVQNZTOKJWJS-ACZMJKKPSA-N 0.000 description 1
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 1
- QHUOOCKNNURZSL-IHRRRGAJSA-N Arg-Tyr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O QHUOOCKNNURZSL-IHRRRGAJSA-N 0.000 description 1
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- QUAWOKPCAKCHQL-SRVKXCTJSA-N Asn-His-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N QUAWOKPCAKCHQL-SRVKXCTJSA-N 0.000 description 1
- WQLJRNRLHWJIRW-KKUMJFAQSA-N Asn-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)N)N)O WQLJRNRLHWJIRW-KKUMJFAQSA-N 0.000 description 1
- RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 1
- RBOBTTLFPRSXKZ-BZSNNMDCSA-N Asn-Phe-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RBOBTTLFPRSXKZ-BZSNNMDCSA-N 0.000 description 1
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 1
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 1
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 1
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 1
- HSWYMWGDMPLTTH-FXQIFTODSA-N Asp-Glu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HSWYMWGDMPLTTH-FXQIFTODSA-N 0.000 description 1
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 1
- GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 1
- VNXQRBXEQXLERQ-CIUDSAMLSA-N Asp-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N VNXQRBXEQXLERQ-CIUDSAMLSA-N 0.000 description 1
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- NDUSUIGBMZCOIL-ZKWXMUAHSA-N Cys-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N NDUSUIGBMZCOIL-ZKWXMUAHSA-N 0.000 description 1
- BPHKULHWEIUDOB-FXQIFTODSA-N Cys-Gln-Gln Chemical compound SC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BPHKULHWEIUDOB-FXQIFTODSA-N 0.000 description 1
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 1
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 1
- KSMSFCBQBQPFAD-GUBZILKMSA-N Cys-Pro-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 KSMSFCBQBQPFAD-GUBZILKMSA-N 0.000 description 1
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001212789 Dynamis Species 0.000 description 1
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 1
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 1
- GNMQDOGFWYWPNM-LAEOZQHASA-N Gln-Gly-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(O)=O GNMQDOGFWYWPNM-LAEOZQHASA-N 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 1
- JILRMFFFCHUUTJ-ACZMJKKPSA-N Gln-Ser-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O JILRMFFFCHUUTJ-ACZMJKKPSA-N 0.000 description 1
- WPJDPEOQUIXXOY-AVGNSLFASA-N Gln-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WPJDPEOQUIXXOY-AVGNSLFASA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 1
- NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 1
- AAJHGGDRKHYSDH-GUBZILKMSA-N Glu-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O AAJHGGDRKHYSDH-GUBZILKMSA-N 0.000 description 1
- BFEZQZKEPRKKHV-SRVKXCTJSA-N Glu-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O BFEZQZKEPRKKHV-SRVKXCTJSA-N 0.000 description 1
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 description 1
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 1
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 1
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 1
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 1
- IXKRSKPKSLXIHN-YUMQZZPRSA-N Gly-Cys-Leu Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O IXKRSKPKSLXIHN-YUMQZZPRSA-N 0.000 description 1
- BIRKKBCSAIHDDF-WDSKDSINSA-N Gly-Glu-Cys Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O BIRKKBCSAIHDDF-WDSKDSINSA-N 0.000 description 1
- AFWYPMDMDYCKMD-KBPBESRZSA-N Gly-Leu-Tyr Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFWYPMDMDYCKMD-KBPBESRZSA-N 0.000 description 1
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 1
- TVMNTHXFRSXZGR-IHRRRGAJSA-N His-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O TVMNTHXFRSXZGR-IHRRRGAJSA-N 0.000 description 1
- ALPXXNRQBMRCPZ-MEYUZBJRSA-N His-Thr-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ALPXXNRQBMRCPZ-MEYUZBJRSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 1
- NPAYJTAXWXJKLO-NAKRPEOUSA-N Ile-Met-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N NPAYJTAXWXJKLO-NAKRPEOUSA-N 0.000 description 1
- NSPNUMNLZNOPAQ-SJWGOKEGSA-N Ile-Tyr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N NSPNUMNLZNOPAQ-SJWGOKEGSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 description 1
- 101710103841 Interleukin-12 receptor subunit beta-1 Proteins 0.000 description 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- UCUNFLYVYCGDHP-UHFFFAOYSA-N L-methionine sulfone Natural products CS(=O)(=O)CCC(N)C(O)=O UCUNFLYVYCGDHP-UHFFFAOYSA-N 0.000 description 1
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 1
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 1
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 1
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 1
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- MPGHETGWWWUHPY-CIUDSAMLSA-N Lys-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN MPGHETGWWWUHPY-CIUDSAMLSA-N 0.000 description 1
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 1
- NTSPQIONFJUMJV-AVGNSLFASA-N Lys-Arg-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O NTSPQIONFJUMJV-AVGNSLFASA-N 0.000 description 1
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 1
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 1
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 1
- ODTZHNZPINULEU-KKUMJFAQSA-N Lys-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N ODTZHNZPINULEU-KKUMJFAQSA-N 0.000 description 1
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 1
- CAVRAQIDHUPECU-UVOCVTCTSA-N Lys-Thr-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAVRAQIDHUPECU-UVOCVTCTSA-N 0.000 description 1
- QLFAPXUXEBAWEK-NHCYSSNCSA-N Lys-Val-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QLFAPXUXEBAWEK-NHCYSSNCSA-N 0.000 description 1
- XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- 102100023231 Lysosomal alpha-mannosidase Human genes 0.000 description 1
- 101710135169 Lysosomal alpha-mannosidase Proteins 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-AJKRCSPLSA-N N-glycoloyl-beta-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-AJKRCSPLSA-N 0.000 description 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- HXSUFWQYLPKEHF-IHRRRGAJSA-N Phe-Asn-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HXSUFWQYLPKEHF-IHRRRGAJSA-N 0.000 description 1
- YYKZDTVQHTUKDW-RYUDHWBXSA-N Phe-Gly-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N YYKZDTVQHTUKDW-RYUDHWBXSA-N 0.000 description 1
- BWTKUQPNOMMKMA-FIRPJDEBSA-N Phe-Ile-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BWTKUQPNOMMKMA-FIRPJDEBSA-N 0.000 description 1
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 1
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 1
- NXEYSLRNNPWCRN-SRVKXCTJSA-N Pro-Glu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXEYSLRNNPWCRN-SRVKXCTJSA-N 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- KWMUAKQOVYCQJQ-ZPFDUUQYSA-N Pro-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1 KWMUAKQOVYCQJQ-ZPFDUUQYSA-N 0.000 description 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 1
- QKDIHFHGHBYTKB-IHRRRGAJSA-N Pro-Ser-Phe Chemical compound N([C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1 QKDIHFHGHBYTKB-IHRRRGAJSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 1
- OOZJHTXCLJUODH-QXEWZRGKSA-N Pro-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 OOZJHTXCLJUODH-QXEWZRGKSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UEJYSALTSUZXFV-SRVKXCTJSA-N Rigin Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UEJYSALTSUZXFV-SRVKXCTJSA-N 0.000 description 1
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 1
- HZWAHWQZPSXNCB-BPUTZDHNSA-N Ser-Arg-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HZWAHWQZPSXNCB-BPUTZDHNSA-N 0.000 description 1
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 1
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 1
- KNCJWSPMTFFJII-ZLUOBGJFSA-N Ser-Cys-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(O)=O KNCJWSPMTFFJII-ZLUOBGJFSA-N 0.000 description 1
- MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- HMRAQFJFTOLDKW-GUBZILKMSA-N Ser-His-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMRAQFJFTOLDKW-GUBZILKMSA-N 0.000 description 1
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 1
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- LAFLAXHTDVNVEL-WDCWCFNPSA-N Thr-Gln-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O LAFLAXHTDVNVEL-WDCWCFNPSA-N 0.000 description 1
- GKWNLDNXMMLRMC-GLLZPBPUSA-N Thr-Glu-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O GKWNLDNXMMLRMC-GLLZPBPUSA-N 0.000 description 1
- SXAGUVRFGJSFKC-ZEILLAHLSA-N Thr-His-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SXAGUVRFGJSFKC-ZEILLAHLSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- RPECVQBNONKZAT-WZLNRYEVSA-N Thr-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H]([C@@H](C)O)N RPECVQBNONKZAT-WZLNRYEVSA-N 0.000 description 1
- SJPDTIQHLBQPFO-VLCNGCBASA-N Thr-Tyr-Trp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O SJPDTIQHLBQPFO-VLCNGCBASA-N 0.000 description 1
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- NLWCSMOXNKBRLC-WDSOQIARSA-N Trp-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLWCSMOXNKBRLC-WDSOQIARSA-N 0.000 description 1
- SSSDKJMQMZTMJP-BVSLBCMMSA-N Trp-Tyr-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 SSSDKJMQMZTMJP-BVSLBCMMSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 1
- SLCSPPCQWUHPPO-JYJNAYRXSA-N Tyr-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SLCSPPCQWUHPPO-JYJNAYRXSA-N 0.000 description 1
- GZUIDWDVMWZSMI-KKUMJFAQSA-N Tyr-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GZUIDWDVMWZSMI-KKUMJFAQSA-N 0.000 description 1
- WURLIFOWSMBUAR-SLFFLAALSA-N Tyr-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O WURLIFOWSMBUAR-SLFFLAALSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 1
- KTEZUXISLQTDDQ-NHCYSSNCSA-N Val-Lys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KTEZUXISLQTDDQ-NHCYSSNCSA-N 0.000 description 1
- SBJCTAZFSZXWSR-AVGNSLFASA-N Val-Met-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N SBJCTAZFSZXWSR-AVGNSLFASA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- TVGWMCTYUFBXAP-QTKMDUPCSA-N Val-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N)O TVGWMCTYUFBXAP-QTKMDUPCSA-N 0.000 description 1
- GVNLOVJNNDZUHS-RHYQMDGZSA-N Val-Thr-Lys Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O GVNLOVJNNDZUHS-RHYQMDGZSA-N 0.000 description 1
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 1
- ZHWZDZFWBXWPDW-GUBZILKMSA-N Val-Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O ZHWZDZFWBXWPDW-GUBZILKMSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012575 bio-layer interferometry Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 description 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 108010071635 tyrosyl-prolyl-arginine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to a method for preparing anti-IL-12 and/or IL-23 monoclonal antibody, in particular to a method for preparing Usunitumumab. Compared with antibodies expressed by SP2/0 cells and CHO-K1 cells, the antibody obtained by the method has higher yield, simple screening steps and higher biological activity.
Description
Cross Reference to Related Applications
The present application claims priority of patent application No.202110174184.3 entitled "a method for preparing monoclonal antibodies against IL-12 and/or IL-23" filed on 9/2/2021 with the intellectual property office of china, the contents of which are incorporated herein by reference in their entirety.
Technical Field
The invention relates to a method for preparing anti-IL-12 and/or IL-23 monoclonal antibody, in particular to a method for preparing Usunitumumab.
Background
Interleukins are a class of cytokines that are produced by and act on a wide variety of cells. Interleukin-12 (IL-12) is a cytokine with a wide range of biological activities, produced mainly by B cells and macrophages, and its molecule is a heterodimer, consisting of two subunits, p35 and p 40. The structure of interleukin-23 (IL-23) has homology with IL-12, exists in a heterodimer form, has an alpha chain of p19 and contains 189 amino acids, and a beta chain of the alpha chain is the same as p40 of IL-12. Its function is to activate stimulated T cells, promote their proliferation and production of interferon gamma, and induce proliferation of memory T cells. IL-12 and IL-23 play an important role in a series of processes such as maturation, activation, proliferation and immunoregulation of immune cells, and in addition, they are involved in various physiological and pathological reactions of the body.
As IL-12 and IL-23 are involved in various disorders, several therapeutic strategies have been devised to inhibit IL-12 and/or IL-23 activity. Among them, the drug "Ustekinumab" of Qiangsheng corporation was approved by the US FDA in 2009 and marketed, and is used for treating adult patients with moderate and severe plaque psoriasis. The Usunitumumab is an IgG1 antibody of a common subunit p40 of targeted IL-12 and IL-23, is a fully human monoclonal antibody, and can inhibit the biological activity of IL-12 and IL-23, thereby preventing the initial T cells from differentiating to Th1 and Th17 cells and further inhibiting the development of inflammatory response. Ubsunitumumab has been approved for the treatment of plaque psoriasis, psoriatic arthritis and crohn's disease in both the united states and europe, and ubsunitumumab has been approved for the treatment of moderate-severe plaque psoriasis and adult crohn's disease indications in china.
Usunuzumab of Qiangsheng corporation is an antibody expressed by SP2/0 cell, and the antibody expressed by mouse myeloma cell SP2/0 has low yield and strong immunogenicity (because of containing NGNA sialylation and alpha-1, 3 galactosylation). Therefore, there is a need to develop a new method for expressing antibodies, which further improves the yield and reduces the immunogenicity while ensuring the biological activity of the antibodies.
Disclosure of Invention
In a first aspect, the present invention provides a method of producing an anti-IL-12 and/or IL-23 monoclonal antibody or an antigen-binding fragment thereof, comprising expressing said monoclonal antibody or said antigen-binding fragment using a DHFR knockout or GS knockout CHO cell, said monoclonal antibody or said antigen-binding fragment comprising a heavy chain variable region comprising VH-CDR1, VH-CDR2 and VH-CDR3 having the amino acid sequences shown in SEQ ID No. 1, SEQ ID No.2 and SEQ ID No. 3, respectively; the light chain variable region comprises VL-CDR1, VL-CDR2 and VL-CDR3 which have the amino acid sequences shown in SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6, respectively.
In one embodiment, the anti IL-12 and/or IL-23 monoclonal antibody or antigen binding fragment thereof contains SEQ ID NO. 7 heavy chain variable region and SEQ ID NO. 8 light chain variable region.
In one embodiment, the monoclonal antibody is an ubsunno monoclonal antibody.
Through a large number of experiments, the inventor unexpectedly finds that the monoclonal antibody expressed by DHFR gene knockout CHO cells or GS gene knockout CHO cells has unexpectedly higher biological activity and higher yield compared with antibodies expressed by SP2/0 cells and CHO-K1 cells.
In one embodiment, the invention provides a method of preparing an anti IL-12 and/or IL-23 monoclonal antibody or antigen binding fragment thereof, the method comprises the following steps:
a) cloning the coding sequence of the anti-IL-12 and/or IL-23 monoclonal antibody or antigen binding fragment thereof into an expression vector to obtain a recombinant expression vector, wherein the expression vector preferably contains a selection marker gene, and more preferably the selection marker gene is a DHFR gene or a GS gene;
b) transferring the recombinant expression vector obtained in the step a) into a CHO cell with a DHFR gene knockout or a CHO cell with a GS gene knockout to obtain a CHO cell modified by genetic engineering;
c) culturing the genetically engineered CHO cell obtained in step b), and selecting a monoclonal cell strain expressing the antibody;
d) culturing the monoclonal cell strain expressing the antibody obtained in the step c), harvesting a cell culture solution containing the antibody, and separating and purifying to obtain the monoclonal antibody.
In one embodiment, the method comprises the steps of:
a) cloning the coding sequence of the anti-IL-12 and/or IL-23 monoclonal antibody or the antigen binding fragment thereof into an expression vector to obtain a recombinant expression vector, wherein the expression vector preferably contains a selection marker gene, and more preferably the selection marker gene is a DHFR gene or a GS gene;
b) transferring the recombinant expression vector obtained in the step a) into a CHO cell with a DHFR gene knockout or a CHO cell with a GS gene knockout to obtain a CHO cell modified by genetic engineering;
c) culturing the genetically engineered CHO cell obtained in step b), and selecting a monoclonal cell strain which can efficiently express the antibody;
d) culturing the monoclonal cell strain which is obtained in the step c) and efficiently expresses the antibody, harvesting a cell culture solution containing the antibody, and separating and purifying to obtain the monoclonal antibody.
In one embodiment, the DHFR gene knockout CHO cell is a CHO-DG44 cell.
In one embodiment, the GS gene knockout CHO cell is obtained by knocking out the GS gene using Zinc Finger Nuclease (ZFN) technology or using CRISPR methods.
In one embodiment, the method comprises the steps of:
a) cloning the coding sequence of the anti-IL-12 and/or IL-23 monoclonal antibody or the binding fragment thereof into an expression vector to obtain a recombinant expression vector, wherein the expression vector contains a GS gene;
b) transferring the recombinant expression vector obtained in the step a) intoGS cells, genetically engineered-a GS cell;
c) genetically engineering the gene obtained in step b)-culturing GS cells in a glutamine-free medium and selecting a monoclonal cell line expressing said antibody;
d) culturing the monoclonal cell strain expressing the antibody obtained in the step c), harvesting a cell culture solution containing the antibody, and separating and purifying to obtain the monoclonal antibody.
In one embodiment, the cell culture process described in step d of the method is in fed-batch mode.
In a second aspect of the invention provides an anti IL-12 and/or IL-23 monoclonal antibody or antigen binding fragment thereof, through the first aspect of the method of the preparation.
In a third aspect, the invention provides a pharmaceutical composition, which comprises the monoclonal antibody prepared by the method of the first aspect, sucrose, L-histidine hydrochloride monohydrate and polysorbate 80.
In one embodiment, the pharmaceutical composition comprises 90 + -9 mg/mL of the monoclonal antibody prepared by the method of the first aspect of the invention, 76 + -7.6 mg/mL of sucrose, 0.5 + -0.3 mg/mL of L-histidine, 1 + -0.5 mg/mL of L-histidine hydrochloride monohydrate, and 800.04 + -0.004 mg/mL of polysorbate.
In one embodiment, the pharmaceutical composition comprises 90mg/mL of the monoclonal antibody prepared by the method of the first aspect of the invention, 76mg/mL of sucrose, 0.636mg/mL of L-histidine, 1.237mg/mL of L-histidine hydrochloride monohydrate, and 800.04mg/mL of polysorbate.
In a fourth aspect, the invention provides a pharmaceutical composition, which comprises the monoclonal antibody prepared by the method of the first aspect, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, disodium EDTA dihydrate and L-methionine.
In one embodiment, the pharmaceutical composition comprises 5 + -0.5 mg/mL of the monoclonal antibody prepared by the method of the first aspect of the invention, 0.77 + -0.077 mg/mL of L-histidine, 1.03 + -0.10 mg/mL of L-histidine hydrochloride monohydrate, 800.4 + -0.04 mg/mL of polysorbate, 85 + -8.5 mg/mL of sucrose, 0.02 + -0.002 mg/mL of EDTA disodium salt dihydrate and 0.4 + -0.04 mg/mL of L-methionine.
In one embodiment, the pharmaceutical composition comprises 5mg/mL of the monoclonal antibody prepared by the method of the first aspect of the invention, 0.77mg/mL of L-histidine, 1.03mg/mL of L-histidine hydrochloride monohydrate, 800.4 mg/mL of polysorbate, 85mg/mL of sucrose, 0.02mg/mL of disodium EDTA dihydrate, and 0.4mg/mL of L-methionine.
In a fifth aspect, the invention provides the method of the first aspect of the invention prepared by anti IL-12 and/or IL-23 monoclonal antibody or antigen binding fragments thereof or the third or fourth aspect of the invention of the pharmaceutical composition for the preparation of treatment of IL-12 and/or IL-23 associated diseases or disorders in the drug.
In one embodiment, the disease or disorder is selected from plaque psoriasis, psoriatic arthritis, crohn's disease, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, sarcoidosis, central spine arthritis, and ankylosing spondylitis. Preferably, the disease or disorder is selected from plaque psoriasis, psoriatic arthritis and crohn's disease.
The invention has the following beneficial effects:
1. the inventor unexpectedly finds that the monoclonal antibody produced by the method has the inhibiting activity on IL-12 and/or IL-23 which is more than 20 percent higher than that of the original medicine. By adopting the technical means of the invention, the inhibitory activity of the monoclonal antibody on IL-12 and/or IL-23 can be obviously improved.
2. The monoclonal antibody produced by the method has the yield as high as about 1.5 g/L.
Detailed Description
Interleukin-12 (also known as IL-12, cytotoxic lymphocyte maturation factor or natural killer cell stimulating factor) is a heterodimer composed of a p35 subunit and a p40 subunit, and many studies have shown that IL-12 plays a key role in promoting the Th1 immune response and in promoting host defense against intracellular pathogens. In addition, IL-12 may promote the development of several autoimmune and inflammatory diseases in driving a Th1 response. Interleukin-23 (IL-23) is a heterodimer consisting of the IL-12p40 subunit and its own p19 subunit, the receptor system of which shares the IL-12R β 1 subunit with IL-12R (. beta.1 and. beta.2), and the specific receptor subunit of which is IL-23R.
The biological effects of IL-12 and IL-23 differ from each other. IL-12 is secreted by activated inflammatory cells (monocytes, macrophages, neutrophils, microglia, dendritic cells). In the inflammatory process, IL-12 induces the production of interferon-gamma (IFN-. gamma.) by NK cells (natural killer cells) and T cells. IL-12 may then be combined with IFN-gamma to induce differentiation of T cells into Th1 cells. This response stimulates the cellular immune system and maximizes the killing effect of macrophages on pathogens and CD8+Proliferation of T cells (Trinchieri 2003Nat Rev Immunol 3133-46). Overproduction of IL-12 is associated with increased pro-inflammatory activity and tissue damage typical of autoimmunity (Leonard et al, 1997Crit Rev Immunol 17545-53). Dysregulation of IL-12 production is implicated in the following diseases: psoriasis (Yawalkar et al, 1998J Invest Dermatol 1111053-7), Crohn's disease (Neurath et al, 1995J Exp Med 1821281-90; simpson et al A,1998J Exp Med 1871225-34; camoglio et al, 2002Eur J Immunol 32261-9), multiple sclerosis (fasbender et al, 1998Neurology 51753-8; laman et al, 1998J neuro-immumunal 8630-45), rheumatoid arthritis (Kim et al, 2000 Clin Exp Immunol 119175-81), and other autoimmune diseases.
Since IL-12 and IL-23 contain common subunits, it is difficult to attribute a disease state to the overproduction of one interleukin or the other alone. However, studies have shown that dysregulation of IL-23 is involved in the following diseases: psoriasis (Lee et al, 2004J Exp Med 199125-30), Crohn's disease (Neurath 2007Nat Med 1326-8) and multiple sclerosis (Cua et al, 2003Nature 421744-8), among other autoimmune diseases.
The invention of the "anti IL-12 and/or IL-23 monoclonal antibody or antigen binding fragment thereof" refers to the ability to specific binding IL-12 and/or IL-23 antibody or antigen binding fragment thereof, preferably, anti IL-12 and/or IL-23 monoclonal antibody or antigen binding fragment thereof "binding IL-12 and/or IL-23, resulting in IL-12 and/or IL-23 biological activity inhibition; more preferably, anti IL-12 and/or IL-23 monoclonal antibody or antigen binding fragment thereof is anti IL-12 and IL-23 monoclonal antibody or antigen binding fragment thereof, causing IL-12 and/or IL-23 biological activity inhibition; more preferably, the heavy chain variable region of the monoclonal antibody comprises: VH-CDR1, VH-CDR2 and VH-CDR3 having the amino acid sequences shown in SEQ ID NO. 1, SEQ ID NO.2 and SEQ ID NO. 3, respectively; the light chain variable region of the monoclonal antibody comprises: VL-CDR1, VL-CDR2 and VL-CDR3 having amino acid sequences shown in SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6, respectively; more preferably, the monoclonal antibody comprises the heavy chain variable region shown in SEQ ID NO. 7 and the light chain variable region shown in SEQ ID NO. 8; most preferably, the monoclonal antibody is ubsunumab. As used herein, the term "inhibit" refers to a decrease in the biological activity of a cytokine when an antibody specifically binds to the cytokine. Inhibition of the biological activity of IL-12 and/or IL-23 by an antibody can be assessed by measuring one or more indicators of the biological activity of IL-12 and/or IL-23, which are well known in the art.
The term "Ustunzumab" refers to a product having the trade name UstunzumabThe fully human IgG1 kappa antibody of (1), which binds to the p40 subunit of IL-12 and IL-23, thereby blocking the inflammatory response in the patient. The heavy chain and light chain sequences of the ubsunumab are as set forth in SEQ ID NO: 9 and SEQ ID NO: shown at 10. On the market, omeprazole has obtained approval for the treatment of moderate to severe plaque psoriasis, active psoriasis, and moderate to severe active crohn's disease. Ulvacizumab in China has been approved for the treatment of moderate to severe plaque psoriasis and adult Crohn's disease indications
In the present invention, the term "standard" is used to indicate that a comparison is made with a biologically similar product, a standard being a product that has gained market acceptance. In the case where the antibody prepared is ubsunumab, the standard is approvedAnd (5) producing the product.
The term "CHO cell" as used herein, derived from epithelial cells of the ovary of Chinese hamster (Tijo and Puck (1958) J. exp. Med.108: 259-271); the term "genetically engineered CHO cells" refers to CHO cells that have been modified or altered by any suitable genetic means and methods known to those skilled in the art such that they express a particular protein. Preferably, the genetically engineered CHO cell may express the monoclonal antibody or antigen binding fragment thereof. More preferably, the genetically engineered CHO cell is obtained by transfecting a recombinant expression vector containing a coding sequence of the monoclonal antibody or the antigen binding fragment thereof into a corresponding CHO cell line. Preferably, the CHO cell is a dihydrofolate reductase (DHFR) gene knockout or a Glutamine Synthetase (GS) gene knockout CHO cell; preferably, the DHFR gene knockout CHO cell is a CHO-DG44 cell. Preferably, the GS gene knockout CHO cell knocks out GS by using Zinc Finger Nuclease (ZFN) technology or using CRISPR methodA gene is thus obtained; more preferably, the GS gene knockout CHO cell is-a GS cell.
As used herein, "CHO-DG 44 cells" refers to CHO cells in which the biallelic dihydrofolate reductase (DHFR) gene has been knocked out, and is a mammalian cell expression system developed by Thermo-Fisher that is currently widely used for recombinant protein expression. Herein, GS Gene knockout CHO cell such as one that knocks out the GS Gene using Zinc Finger Nuclease (ZFN) technology or using CRISPR method, for example, Merck's CHO cellGS mammalian cell expression System, usingEndogenous Glutamine Synthetase (GS) genes of CHO-K1 cell strains are knocked out by a Zinc Finger Nuclease (ZFN) technology, so that the cell growth process must depend on the addition of exogenous L-glutamine to form a natural screening marker, and the dependence of a GS screening system on L-methionine sulfone imine (MSX) is also eliminated. The plasmid is not transferred into the culture medium with glutamine, but the plasmid (with GS gene) can survive in the culture medium without glutamine, so that the high expression cell strain is screened without adding MSX and other resistance screening matter, and this simplifies the screening process and makes the process suitable for industrial production.
The inventors have unexpectedly found, through a large number of experiments, that CHO cells or GS (glutamine synthetase) cells, in particular CHO-DG44 cells or CHO-DG44 cells, which were knocked out using DHFR (dihydrofolate reductase) geneGS cells expressing said monoclonal antibody, with higher biological activity, higher yield, lower immunogenicity and higher cell stability than those expressed by SP2/0 cells and CHO-K1 cells, in particular UsunuzumabGood, the screening step is simple.
The method for preparing the monoclonal antibody comprises the following steps:
a) cloning the coding sequence of the monoclonal antibody into an expression vector to obtain a recombinant expression vector, wherein the expression vector preferably contains a selection marker gene, and more preferably the selection marker gene is a DHFR gene or a GS gene;
b) transferring the recombinant expression vector obtained in the step a) into a CHO cell with a DHFR gene knockout or a CHO cell with a GS gene knockout to obtain a CHO cell modified by genetic engineering;
c) culturing the genetically engineered CHO cell obtained in step b), and selecting a monoclonal cell strain expressing the antibody;
d) culturing the monoclonal cell strain expressing the antibody obtained in the step c), harvesting a cell culture solution containing the antibody, and separating and purifying to obtain the monoclonal antibody.
Methods for constructing recombinant expression vectors suitable for expressing antibodies in CHO cells are well known to those skilled in the art, for example, in Makrides et al (1999) Protein Expr. Purif.17:183-202 and Kaufman (2000) mol. Biotechnol.16: 151-161. The expression vector refers to a vector, such as a recombinant plasmid, which can express a target gene by adding expression elements (such as a promoter, a terminator and the like) on the basis of a basic skeleton of a cloning vector. Preferably, the expression vector contains a selectable marker gene. The selectable marker gene encodes a protein as described below: (a) conferring resistance to antibiotics or other toxins, (b) supplementing auxotrophic deficiencies, or (c) providing key nutrients not available from complex media. More preferably, the selectable marker gene is a dihydrofolate reductase gene or a glutamine synthetase gene. Methods for genetically engineering CHO cells are well known to those skilled in the art and specifically include co-transfecting CHO cells with one expression vector containing genes encoding the heavy and light chains of an antibody or a first expression vector containing genes encoding the heavy chain of an antibody and a second expression vector containing genes encoding the light chain of an antibody. Will recombineMethods for transferring expression vectors into CHO cells include electroporation, calcium phosphate precipitation, lipofection, DEAE-dextran transfection, and the use of commercial transfection kits, such as FreeStyle from Thermo fisher ScientificTMMAX Reagent, etc.
Culturing the obtained genetically engineered CHO cells in a culture medium to obtain a monoclonal cell strain capable of efficiently expressing the antibody. Wherein, for CHO cells with DHFR (dihydrofolate reductase) gene knockout, corresponding inhibitors such as Methotrexate (MTX) and the like are added into a target culture medium according to a selection marker gene carried on a transfected recombinant expression vector,And the like, thereby obtaining a cell line capable of efficiently expressing the antibody; for the CHO cell with GS (glutamine synthetase) gene knockout, because the cell can survive in the culture medium with glutamine when the plasmid is not transferred and can survive in the culture medium without glutamine when the plasmid is transferred (the GS gene is on the plasmid), the cell strain which can express the antibody with high efficiency can be obtained by culturing in the culture medium without glutamine, Methionine Sulphonamide (MSX) is not added in the culture medium,and the like. Then carrying out monoclonal screening to obtain a monoclonal cell strain expressing the antibody; preferably, a monoclonal cell strain capable of expressing the antibody with high efficiency is obtained.
The obtained genetically engineered CHO cells were cultured in an appropriate medium to produce antibodies. "culture medium" as described herein, refers to a solution containing nutrients required for mammalian cell growth. In general, the culture medium provides essential and non-essential amino acids, vitamins, energy sources, lipids, and trace elements required by the cells.
There are different culture modes for genetically engineered CHO cells, including batch, continuous and fed-batch. In the present invention, it is preferable to produce an antibody using a fed-batch culture mode. In fed-batch culture, the culture is started with a certain amount of medium, and during the subsequent culture, one or more nutrients are supplemented in order to prevent the depletion of nutrients, during which no product is removed from the cell culture medium.
After antibody production by genetically engineered CHO cells, since recombinant proteins expressed from mammalian cells, particularly antibodies, are usually secreted into the cell culture broth during the culture process, the antibodies are harvested by separating the cell culture broth containing the antibodies from the cells at the end of the culture process. Cell separation methods should minimize cell lysis, avoid the increase in cell debris, and release proteases and other molecules that may affect the quality of the immunoglobulin product. The cell culture fluid containing the antibody is typically obtained by means of centrifugation and/or filtration, the recombinant protein being present in the supernatant or filtrate, respectively.
After obtaining the cell culture fluid containing the antibody, the antibody is purified from the cell culture fluid. Purification of recombinant proteins is typically accomplished by a series of chromatographic steps, such as anion exchange chromatography, cation exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, hydroxyapatite chromatography, and the like. Purification of recombinant antibodies typically begins with ProteinA affinity chromatography followed by one or more additional chromatography steps, such as cation exchange chromatography. Further, the purification step may include ultrafiltration, diafiltration, and the like.
As described above, the inventors found that the ubsumab antibody standard substance produced by the method of the present inventionThe product has higher bioactivity. The biological activity of Ustuzumab is expressed by the ability to bind to IL-23, the ability to bind to IL-12, the ability to bind to FcRn and/or the inhibition of IL-12 and/or IL-23 induced gene expression, in particular the inhibition of IL-12 and/or IL-23 induced gene expression. The ability of ubsumab to bind to IL-23, IL-12 or FcRn can be assessed by, but is not limited to, ELISA and biolayer interferometry; gene table induced by Usunitumumab on IL-12Inhibition of expression can be studied by assaying samples for cells that are reactive to IL-12 (e.g., T lymphocytes), IL-12 and antibodies, and then detecting the production of a target molecule, such as interferon-gamma (IFN-gamma). The target molecule interferon-gamma (IFN-gamma) may be detected and/or quantified by any suitable method, such as ELISA.
The inhibitory action of the Usneuzumab produced by the method on the generation of IFN-gamma is larger than that of a standard product on the generation of IFN-gamma, and the inhibitory action of the Usneuzumab produced by the method on the generation of IFN-gamma exceeds that of the standard product on the generation of IFN-gamma by more than 20%.
The invention also relates to a pharmaceutical composition containing the anti-IL-12 and/or IL-23 monoclonal antibody or antigen binding fragment thereof prepared by the method. In addition to comprising the monoclonal antibody, the pharmaceutical composition of the invention further comprises at least one pharmaceutically acceptable excipient. Pharmaceutically acceptable excipients are substances which do not affect the physiological activity of the active substance, such as ubenizumab, and which are capable of stabilizing the pharmaceutical ingredients and/or increasing the solubility or reducing the viscosity of the pharmaceutical composition. Common pharmaceutical excipients for monoclonal antibodies include buffers, salts, sugars or sugar alcohols, amino acids and surfactants.
In one embodiment, a pharmaceutical composition comprises the monoclonal antibody, sucrose, L-histidine hydrochloride monohydrate, and polysorbate 80; preferably, the pharmaceutical composition comprises the monoclonal antibody 90 + -9 mg/mL, sucrose 76 + -7.6 mg/mL, L-histidine 0.5 + -0.3 mg/mL, L-histidine hydrochloride monohydrate 1 + -0.5 mg/mL, and polysorbate 800.04 + -0.004 mg/mL. More preferably, the pharmaceutical composition comprises the monoclonal antibody 90mg/mL, sucrose 76mg/mL, L-histidine 0.636mg/mL, L-histidine hydrochloride monohydrate 1.237mg/mL, and polysorbate 800.04 mg/mL.
In another embodiment, a pharmaceutical composition comprises the monoclonal antibody, sucrose, L-histidine hydrochloride monohydrate, EDTA disodium salt dihydrate, L-methionine and polysorbate 80. Preferably, the pharmaceutical composition comprises: the monoclonal antibody is 5 +/-0.5 mg/mL, the L-histidine is 0.77 +/-0.077 mg/mL, the L-histidine hydrochloride monohydrate is 1.03 +/-0.10 mg/mL, the polysorbate is 800.4 +/-0.04 mg/mL, the sucrose is 85 +/-8.5 mg/mL, the disodium EDTA dihydrate is 0.02 +/-0.002 mg/mL, and the L-methionine is 0.4 +/-0.04 mg/mL. More preferably, the pharmaceutical composition comprises: the monoclonal antibody is 5mg/mL, the L-histidine is 0.77mg/mL, the L-histidine hydrochloride monohydrate is 1.03mg/mL, the polysorbate is 800.4 mg/mL, the sucrose is 85mg/mL, the disodium EDTA dihydrate is 0.02mg/mL, and the L-methionine is 0.4 mg/mL.
The anti-IL-12 and/or IL-23 monoclonal antibody or antigen binding fragment thereof or the pharmaceutical composition can be used for preparing a medicament for treating IL-12 and/or IL-23 related diseases or disorders; preferably, the disease or disorder is selected from plaque psoriasis, psoriatic arthritis, systemic lupus erythematosus, crohn's disease, ulcerative colitis, multiple sclerosis, sarcoidosis, central spine arthritis, and ankylosing spondylitis. More preferably, the disease or disorder is selected from plaque psoriasis, psoriatic arthritis and crohn's disease.
In one embodiment, the anti-IL-12 and/or IL-23 monoclonal antibodies or antigen-binding fragments thereof or the pharmaceutical compositions described herein are useful for treating plaque psoriasis, particularly in treating adults with moderate to severe plaque psoriasis, patients who are unresponsive or intolerant to other systemic therapies, including cyclosporine, Methotrexate (MTX) or PUVA (psoralen and ultraviolet a), and in treating patients who are 12 years old and older, in adolescent to severe plaque psoriasis, who are inadequately controlled or intolerant to other systemic therapies or phototherapy therapies, and in treating psoriatic arthritis, particularly in treating active psoriasis, in adult patients who have been inadequately treated with previously non-biological disease modifying antirheumatic drugs (DMARDs).
In another embodiment the anti-IL-12 and/or IL-23 monoclonal antibodies or antigen-binding fragments thereof or the pharmaceutical compositions of the invention are useful for the treatment of Crohn's disease, in particular adult patients with moderate to severe active Crohn's disease, who are poorly responsive, unresponsive, intolerant or medically contraindicated to conventional therapies or TNF-a antagonists.
A composition or method described herein as "comprising" or "including" one or more named elements or steps is open-ended, meaning that the named elements or steps are necessary, but that other elements or steps may be added within the scope of the composition or method. Known or disclosed equivalents of any named base element or step may be substituted for the recited element or step in any composition or method disclosed herein.
Detailed Description
Example 1 construction of CHO-DG44 cell line expressing Usunitumumab
Vector construction
(1) Preparation of antibody heavy chain protein expression vector
Two ends of a coding sequence (SEQ ID No:11) of the Usunuzumab heavy chain are designed with two enzyme cutting sites of BamHI and Xhol, which are respectively connected with the BamHI and Xhol enzyme cutting sites on an expression vector pCDNA3.1 (purchased from Thermo Fisher Scientific company) to realize the connection of a target protein coding DNA fragment and the expression vector and obtain recombinant plasmid DNA. The recombinant plasmid DNA is introduced into Escherichia coli DH5 a (purchased from Tiangen Biochemical technology Co., Ltd.), single colony plasmid is extracted and sent for sequencing, and plasmid with correct sequencing result is obtained and is marked as recombinant plasmid pCDNA-HC.
(2) Preparation of antibody light chain protein expression vector
HindIII and Xhol restriction sites are designed at two ends of a coding sequence (SEQ ID No:12) of a Ustunzumab light chain and are respectively connected with HindIII and Xhol restriction sites on an expression vector pOptiVEC (purchased from Thermo Fisher Scientific company), so that a target protein coding DNA fragment is connected with the expression vector to obtain recombinant plasmid DNA, the recombinant plasmid DNA is introduced into escherichia coli DH5 a (purchased from Tiangen Biotechnology Co., Ltd.), a single colony plasmid is extracted and sent to be sequenced to obtain a plasmid with a correct sequencing result, and the plasmid is marked as recombinant plasmid pOptiVec-LC.
Construction of CHO-DG44 cell strain for expressing Usunitumumab
The recombinant plasmids pOptiVec-LC and pCDNA-HC were linearized, transfected into CHO-DG44 cells (purchased from Thermo Fisher Scientific Co.) and cultured to obtain a cell line highly expressing the target protein. The method comprises the following specific steps:
(1) recombinant plasmid transfected CHO-DG44 cells
The plasmid was linearized using PvuI enzymatic cleavage sites on recombinant plasmids pOptiVec-LC and pCDNA-HC. The enzyme-digested plasmid DNA was concentrated to a concentration of 1ug/ul by ethanol precipitation.
Take 1.5X 107The CHO-DG44 cells were replaced with 30mL of CD DG44 medium (purchased from Thermo Fisher Scientific Co.) preheated to 37 ℃ and mixed well; 60ug of plasmid DNA (pcDNA-HC to pOptiVec-LC molar ratio 1:1) and 15uL FreeStyleTMMAX Reagent (available from Thermo Fisher Scientific Co.) was placed in 1.2mL OptiPROTMSFM medium (purchased from Thermo Fisher Scientific Co.) was gently mixed and incubated at room temperature for 10min to obtain DNA-Reagent complex. 1.2mL of the DNA-Reagent complex was added to 125mL of the CHO-DG44 cell shake flask, the flask was gently shaken, and the flask was placed in a shaker at 37 ℃ with 8% CO2The rotation speed was 130-. 48 hours after transfection, cells were passaged to hypoxanthine/thymine (HT) -deficient CD OptiCHOTMComplete medium (purchased from Gibco Life Technologies, Inc.).
(2) Selection of stably transfected cells
First wheelScreening: counting the cell lines obtained in the last step; in a preheated medium containing 500ug/mLCD OptiCHO of reagent (available from Thermo Fisher Scientific Co.)TMCells were diluted in complete medium (purchased from Gibco Life Technologies) to a final cell density of 5X 105Viable cells/mL; the flask was placed in an incubator at 37 ℃ with 8% CO2Under the condition of humidified air, the rotating speed is 130-. Replacing appropriate amount of fresh culture medium every 2-3 days, and maintaining for 14-21 days untilCell survival rate>90%。
Second round MTX gradient screen: the first round of screened cells were counted, centrifuged at 1000rpm for 5 minutes, the old medium was discarded, and the cells were seeded into CD OptiCHO containing 50nM MTXTMComplete medium (purchased from Gibco Life Technologies, Inc.; containing 500. mu.g/mL)) Inoculation density of 3X 105cells/mL. The flask was placed in an incubator at 37 ℃ with 8% CO2Under the condition of humidified air, the rotating speed is 130-. Changing an appropriate amount of fresh medium every 2-3 days, inoculating cells to CD OptiCHO containing 100nM MTX at a cell viability rate greater than 80%TMComplete medium (purchased from Gibco Life Technologies, Inc.; containing 500. mu.g/mL)) Inoculation density of 3X 105cells/mL, the flasks were placed in an incubator at 37 ℃ with 8% CO2Under the condition of humidified air, the rotating speed is 130-. Changing an appropriate amount of fresh culture medium every 2-3 days, inoculating cells to CD OptiCHO containing 500nM MTX at a cell viability rate of more than 80%TMComplete medium (purchased from Gibco Life Technologies, Inc.; containing 500. mu.g/mL)) Inoculation density of 3X 105cells/mL, total incubation time 20-30 days, until cell viability>90%。
(3) Monoclonal screening and expanded culture
The CELLs obtained in the above step were diluted with a Cloning Medium EX-CELL CHO Cloning Medium (purchased from Sigma Aldrich) in a gradient manner to 1000 viable CELLs/mL, and seeded into a 96-well plate at 0.8 CELLs per well. The inoculated 96-well plate was placed at 37 ℃ with 5% CO2The plate was incubated still in the incubator under the air condition for 10 to 14 days, 11 days in this example, and the wells were examined using a microscopeGrowth of single clone colonies.
When the cells in a 96-well plate grow to reach 80% confluence, the yield of each clone is detected by an ELISA method, specifically, the content of the ubsunitumumab in the fermentation liquor is determined by a double-antibody sandwich method, the coating antibody is a murine monoclonal antibody human IgG Fc fragment antibody (purchased from Sigma under the product number I6260-5 mL), the secondary antibody is a murine monoclonal antibody human IgG Fab fragment antibody (purchased from Kingsler Biotech Co., Ltd under the product number A01855), and the used standard product is original research medicineThe maximum dilution concentration is 1ug/mL, and 12 standards are diluted in a twofold gradient.
The first 25% of clones with high screening yields were clonally expanded, and desired monoclonal cells were aseptically collected and expanded into 24-well plates. After 3-5 days, the first 10% of the higher yield clones were selected and transferred to 6-well plates using the same assay and cultured. Using the same assay, monoclonal cells were selected for the first 10% yield in 6-well plates and each cell line was transferred individually to T-25 flasks for expansion when the number of cells in the T-25 flask reached 1x107Thereafter, the cells were transferred to 125mL culture flasks. At 37 ℃ and with 8% CO2Under the air condition of (1), the oscillation speed is 130-135rpm, the fed-batch culture mode is adopted for culture, and a fed-batch culture medium Dynamis is added in the culture processTMMedium (purchased from Thermo Fisher company) cultured for 14 days, and collected cell fermentation broth of CHO-DG44 cell strain highly expressing ubeniumumab.
Vector construction
(1) Expression of antibody heavy chain protein and vector ligation
Two restriction sites BstB I and Pac I are designed at two ends of a coding sequence of the Usunu monoclonal antibody heavy chain and are respectively connected with the restriction sites BstB I and Pac I on an expression vector pCGS (purchased from Merck KGaA company), so that the connection of a target protein coding DNA fragment and the expression vector is realized, and the recombinant plasmid DNA is obtained. The recombinant plasmid DNA was introduced into E.coli DH5 a (purchased from Tiangen Biochemical technology Co., Ltd.) and applied to LB agar medium (prepared per liter of medium, 950ml of deionized water to which 10g of tryptone, 5g of yeast extract, 10g of NaCl10g, and then deionized water to 1L) containing 100ug/ml of ampicillin (final concentration). The obtained clone was cultured in LB liquid medium containing 100ug/ml ampicillin (final concentration), and plasmids were extracted with a plasmid extraction kit (purchased from Tiangen Biochemical technology Co., Ltd.), identified by nucleic acid sequencing, and plasmids with correct sequencing results were selected and designated as recombinant plasmids pCGS-HC.
(2) The light chain protein of the expression antibody is connected with the carrier
HindIII and Xhol restriction sites are designed at two ends of a coding sequence of the Usunu monoclonal antibody light chain and are respectively connected with HindIII and Xhol restriction sites on the recombinant plasmid pCGS-HC, so that the connection of a target protein coding DNA fragment and an expression vector is realized, and new recombinant plasmid DNA is obtained. The recombinant plasmid DNA was introduced into E.coli DH5 a (purchased from Tiangen Biochemical technology Co., Ltd.) and applied to LB agar medium (prepared per liter of medium, 950ml of deionized water to which 10g of tryptone, 5g of yeast extract, 10g of NaCl, and then 1L of deionized water) containing 100ug/ml of ampicillin (final concentration). The obtained clone was cultured in LB liquid medium containing 100ug/ml ampicillin (final concentration), and plasmids were extracted with a plasmid extraction kit (purchased from Tiangen Biochemical technology Co., Ltd.), identified by nucleic acid sequencing, and plasmids with correct sequencing results were selected and designated as recombinant plasmids pCGS-HC-LC.
Cell line selection
Transfection of recombinant plasmid pCGS-HC-LC intoGS cells (purchased from Merck KGaA) were screened to obtain cell lines highly expressing the target protein. The method comprises the following specific steps:
a. Cells were passaged the day before transfection to a density of 1X10 at transfection6Viable cells/mL.
b. Cell count, total number of cells required per sample 6X 106The desired cells were centrifuged at 1000rpm for 10min in a 50mL centrifuge tube.
c. Each sample was resuspended in 600. mu.L LEX-CELL CD CHO medium (purchased from Sigma Aldrich) and 40. mu.g of plasmid (plasmid concentration > 1. mu.g/. mu.L) was added and mixed well, and then placed in a refrigerator together with an electric rotor for precooling at 4 ℃.
d. The CELLs added with the plasmid are blown uniformly and then added into an electric rotating cup, the voltage is 300V for electric rotation, after the electric rotation is finished, the CELLs are added into a culture medium EX-CELL CD CHO Fusion (purchased from Sigma Aldrich company) containing 6mM glutamine and preheated at 37 ℃, and the CELLs are placed into a carbon dioxide incubator for static culture for 48 hours.
(2) Selection of stably transfected cells
After 48h, the CELLs were passaged to glutamine-free medium EX-CELL CD CHO Fusion (from Sigma Aldrich). Passage was performed every 2 days, with each passage labeled "P1", "P2", where n is the passage of the cell. Before each passage, 40. mu.L of the cell suspension was subjected to cell counting and cell viability analysis using a Countstar IC 1000 automatic cell counter to determine the viable cell density and viability of each generation of cells. When the cell viability was > 95%, the screening process was completed. The process can also be completed by a method of screening a cell pool (minipool).
(3) Monoclonal screening and expanded culture
The cells obtained in the previous step were seeded into 96-well plates, 0.5-1 cells per well.
a. 400mL of complete Cloning Medium EX-CELL CHO Cloning Medium (available from Sigma Aldrich) was preheated to 37 ℃;
b. counting the cells to be plated, and calculating the number of the required cells, namely 20 96-well plates, wherein 960 cells are required for calculation of 0.5 cell per well;
c. continuously diluting cells to a final concentration of 1000 viable cells/mL by using the complete cloning medium, and taking 960uL of cell diluent to a preheated cloning medium;
d. gently mixing the cell suspension, and transferring the cell suspension into a sterile sample adding groove; using a multichannel pipettor, dispense 200 μ Ι _ of the diluted cells into a 96-well plate under sterile conditions;
e. at 37 deg.C, 5% CO2The plate was incubated still in the incubator under air conditions for 10 to 14 days, 11 days in this example, and the growth of the monoclonal colonies in the wells was examined using a microscope.
When the CELLs in the 96-well plate were grown to 80% confluence, the yields of the individual clones were examined by the same ELISA method as in example 1, the first 25% clones with high productivity were selected for clonal expansion, the desired clones were aseptically collected, gently pipetted up and down and the entire contents of each well were transferred to each well of a 24-well plate containing 1mL of fresh medium EX-CELL CD CHO Fusion (available from Sigma Aldrich).
After 3-5 days, using the same assay, the first 10% higher yield clones of interest were selected and transferred to 6-well plates, the desired clones were collected aseptically, and fresh medium EX-CELL CD CHO Fusion was added to each well of the 6-well plates, and finally the culture volume of each well was 3 mL.
Using the same assay, the first 10% yield of monoclonal cell lines in 6-well plates were selected and each cell line was transferred individually to T-25 flasks for expansion when the number of cells in the T-25 flask reached 1x107Thereafter, the cells were transferred to 125mL culture flasks. At 37 ℃ and with 8% CO2Under the air condition of (1), the oscillation speed is 130-135rpm, the fed-batch culture mode is adopted for culture,
during the culture process, a Feed medium EX-CELL Advanced CHO Feed 1 (purchased from Sigma Aldrich company) is added, and after 14 days of culture, the high-expression ubsunobumab is collected-cell fermentation broth of GS cell line.
Example 3 antibody purification procedure
High table to be collectedCHO-DG44 cell strain of dacustitumumab and-cell fermentation broth of GS cell line, subjected to the following operations:
1. centrifugation
Setting the rotating speed of a centrifuge to 3000rpm, centrifuging for 10min, and removing cells; the centrifuge was then set at 15000rpm for 20min to remove cell debris. The step can also adopt a deep filtration method to clarify the cell fermentation liquor.
2. Microfiltration
The samples were microfiltered using a Perl sterile grade filter (pore size 0.22 μm, material polyethersulfone).
3. Elution is carried out
The instrument comprises the following steps: AKTA protein purification apparatus and Mabselect sure LX packing (both from GE Co.)
Reagent: balance liquid: 150mM NaCl, 20mM phosphate buffer pH7.4
Eluent 1: 1M NaCl 20mM sodium citrate pH5.5
Eluent 2: 20mM sodium citrate pH5.5
Eluent: 20mM sodium citrate pH3.0
Regeneration liquid: 0.1M NaOH
The method comprises the following steps: 1) balancing by using the balancing liquid; 2) sampling; 3) leaching: sequentially leaching with leacheate 2, leacheate 1 and leacheate 2; 4) eluting with the eluent; 5) clean In Place (CIP) using 0.5M sodium hydroxide; 6) rebalancing: the above-mentioned equilibrium liquid was used for equilibration.
The Usunuzumab product with the purity of 97% is finally obtained by using the CHO-DG44 cell strain to produce the Usunuzumab, and the yield is about 1.5 g/L.
Use ofAnd producing the Usunuzumab by using the cells of the GS cell strain to finally obtain the Usunuzumab product with the purity of 98 percent, wherein the yield is about 1.5 g/L.
Example 4 Usunitumumab expressed by CHO-DG44 cells had inhibitory Activity on IL-12
Isolation and activation of T cells
Peripheral Blood Mononuclear Cells (PBMC) from Redbold were sorted for total CD3 by removing non-T cells with magnetic bead sorting reagent (STEM Cell) according to the EasySep Human T Cell Isolation Kit protocol+T cells. T cells at a concentration of 1x106The culture was carried out in 12-well plates in 1640 medium (from Sigma Aldrich) containing 10% FBS (fetal bovine serum) (Gibco Life Technologies) or in TexMACX medium (from Miltenyi Biotec) in the absence of serum, and in the case of T-cells, the stimulator anti-CD3/CD28 antibody (from Thermo Fisher Scientific) was added together with IL-2(30u/mL) (from Thermo Fisher Scientific).
Mixing 1.0X 106ml-1T cells were pre-stimulated with magnetic beads to produce interferon-gamma (IFN-gamma), and 2 days later, the cell concentration was adjusted to 0.5X 10 by centrifugation of the medium on day 36ml-1(exchange liquid into TexMACX medium).
IL-12 ELISA
The strips required for the assay were removed from the sealed bags equilibrated to room temperature using a human IFN-. gamma.ELISA kit (purchased from Shanghai Eikes Co.) leaving blank wells. Regulating the T cells obtained in the previous step to 0.5X 105IL-12, the inventive Usunuzumab sample (hereinafter, referred to as "sample") and a standard were added to the corresponding wells (100 ul/well) in the amounts shown in Table 1, respectively, and cell activity experiments were performed according to the design of Table 1. The reaction wells were sealed with a sealing plate of gummed paper and incubated at 37 ℃ for 90 minutes in an incubator. Plates were washed 5 times and biotinylated antibody working solution (100 ul/well) was added except for blank wells. The reaction wells were sealed with a sealing plate of gummed paper and incubated at 37 ℃ for 60 minutes in an incubator. The plate was washed 5 times and the enzyme conjugate working solution (100 ul/well) was added except for blank wells. The reaction wells were sealed with a sealing plate gummed paper, incubated at 37 ℃ for 30 minutes in the dark. The plate was washed 5 times, 100ul of chromogenic substrate (including blank wells) was added per well, incubated at 37 ℃ for 15 minutes in the absence of light. Add stop solution (including blank wells) 100 ul/well and measure OD450nm immediately after mixing.
TABLE 1 cell Activity experiments and results of Usunuzumab samples
Inhibition rate (Abs)(IL-12 average value)–Abs(antibodies))/(Abs(IL-12 average value)–Abs(average value of cell supernatant))
According to the data results and the inhibition rate calculation formula in table 1, the inhibition rate of the Usunitumumab sample expressed by CHO-DG44 on the IL-12 activity is 43.19%, the inhibition rate of the standard product on the IL-12 activity is 34.9%, and the inhibition activity of the Usunitumumab sample expressed by CHO-DG44 on the IL-12 is 23.753% higher than that of the Usunitumumab standard product.
Isolation and activation of T cells
Peripheral Blood Mononuclear Cells (PBMC) from Redbold were sorted for total CD3 by removing non-T cells with magnetic bead sorting reagent (STEM Cell) according to the EasySep Human T Cell Isolation Kit protocol+T cells. T cells at a concentration of 1x106The cells were cultured in 12-well plates in X-vivo (available from Lonza) and, in the case of T-cell culture, the stimulator anti-CD3/CD28 antibody (available from Thermo Fisher Scientific Co.) was added together with IL-2(30u/mL) (available from Thermo Fisher Scientific Co.) added.
Regulatory T cell concentration of 1X106one/mL. Mixing 1.0X 106ml-1T cells were pre-stimulated with magnetic beads to activate them and produce gamma interferon (gamma-IFN), and 2 days after stimulation, the cell concentration was adjusted to 0.3X 10 by centrifugation on day 36ml-1。
IL-12ELISA
This step uses a human IFN-. gamma.ELISA kit (purchased from Shanghai Eikes Co.), removes the 96-well plate of the plate required for the assay from the sealed bag equilibrated to room temperature, and presses IL-12Adding the amount shown in table 2 into a 96-well plate (50 uL/well), adding the inventive ubepratumab sample (hereinafter referred to as "sample") and the standard sample into the corresponding well (50 uL/well) according to the amount shown in table 2, incubating in an incubator for 1h, centrifuging the T cells obtained in the previous step to remove the original culture medium, and adjusting the T cells to 0.3 × 10 with X-vivo5Per well, and then added to the corresponding well (100 uL/well). The reaction wells were sealed with a sealing plate of gummed paper and incubated at 37 ℃ for 90 minutes in an incubator. The plate was washed 5 times and biotinylated antibody working solution (100 ul/well) was added. The reaction wells were sealed with a sealing plate of gummed paper and incubated at 37 ℃ for 60 minutes in an incubator. The plate was washed 5 times and the enzyme conjugate working solution (100 ul/well) was added. The reaction wells were sealed with a sealing plate gummed paper, incubated at 37 ℃ for 30 minutes in the dark. Washing the plate for 5 times, adding 100ul of chromogenic substrate per hole, incubating in an incubator at 37 ℃ and keeping dark for 15 minutes. Add stop solution 100 ul/well and mix well immediately before measuring OD450nm value.
TABLE 2 cellular Activity experiments and results of Usunuzumab samples
From the data in table 2, the inhibition ratio of each antibody as in table 3 was calculated using the following inhibition ratio calculation formula.
Inhibition rate (Abs)(IL-12)–Abs(Standard article))/(Abs(IL-12)–Abs(cell supernatant))
TABLE 3 Experimental results treatment
Antibodies | 0.5ug of standard | 0.5ug sample | 1ug of standard article | 1ug sample |
Inhibition ratio (%) | 9.52 | 11.67 | 27.64 | 37.98 |
It can be calculated that when 0.5ug of Usunitumumab was used in the above experiment,the USTRINOMAB sample expressed in GS had an IL-12 inhibitory activity 22.58% higher than that of USTRINOMAB standard, and when 1ug USTRINOMAB was used in the above experiment,the Usunitumumab sample expressed by GS has 37.41% higher IL-12 inhibition activity than the Usunitumumab standard product.
Through the experimental results of example 4 and example 5, it can be seen that the inhibitory activity of the ubsumizumab sample of the present invention on IL-12 is more than 20% higher than that of the ubsumizumab standard.
Unless otherwise indicated, all starting materials and reagents used in the examples of the present invention are commercially available.
The present invention has been illustrated by the above embodiments, but it should be understood that the above embodiments are for illustrative and descriptive purposes only and are not intended to limit the invention to the scope of the described embodiments. Furthermore, it will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, and that many variations and modifications may be made in accordance with the teachings of the present invention, which variations and modifications are within the scope of the present invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Sequence listing
<110> Ganli pharmaceutical industry Co., Ltd
<120> a method for producing an anti-IL-12 and/or IL-23 monoclonal antibody
<160> 12
<170> SIPOSequenceListing 1.0
<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Thr Tyr Trp Leu Gly
1 5
<210> 2
<211> 17
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Ile Met Ser Pro Val Asp Ser Asp Ile Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 3
<211> 10
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Arg Arg Pro Gly Gln Gly Tyr Phe Asp Phe
1 5 10
<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala
1 5 10
<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Ala Ala Ser Ser Leu Gln Ser
1 5
<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Gln Gln Tyr Asn Ile Tyr Pro Tyr Thr
1 5
<210> 7
<211> 119
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Tyr
20 25 30
Trp Leu Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Asp Trp Ile
35 40 45
Gly Ile Met Ser Pro Val Asp Ser Asp Ile Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Met Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr
65 70 75 80
Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Arg Arg Pro Gly Gln Gly Tyr Phe Asp Phe Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115
<210> 8
<211> 107
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ile Tyr Pro Tyr Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg
100 105
<210> 9
<211> 449
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 9
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Tyr
20 25 30
Trp Leu Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Asp Trp Ile
35 40 45
Gly Ile Met Ser Pro Val Asp Ser Asp Ile Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Met Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr
65 70 75 80
Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Arg Arg Pro Gly Gln Gly Tyr Phe Asp Phe Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Ser Ser Thr Lys Gly Pro Ser Val Phe
115 120 125
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140
Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
145 150 155 160
Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
165 170 175
Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190
Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
195 200 205
Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys
210 215 220
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro
225 230 235 240
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
260 265 270
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
275 280 285
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
290 295 300
Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
325 330 335
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400
Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
405 410 415
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430
Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445
Lys
<210> 10
<211> 214
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 10
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ile Tyr Pro Tyr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 11
<211> 1413
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
gccaccatgg agttcggcct gtcctgggtg ttcctggtgg ccctgttcag gggcgtgcag 60
tgtgaggtgc agctggtgca gtccggcgcc gaggtgaaga agcctggcga gtccctgaag 120
atcagctgca agggctccgg ctactccttc accacatact ggctgggctg ggtgaggcag 180
atgcccggca agggcctgga ttggatcggc atcatgagcc ccgtggatag cgatattagg 240
tacagcccta gcttccaggg ccaggtgaca atgtccgtgg ataagagcat cacaaccgcc 300
tacctgcagt ggaacagcct gaaggccagc gacaccgcca tgtactactg cgccaggaga 360
agacccggcc agggctactt cgacttctgg ggccagggca ccctggtgac agtgagcagc 420
agcagcacca agggccctag cgtgttcccc ctggccccct ctagcaagtc cacctccggc 480
ggcaccgccg ctctgggatg tctggtgaag gactacttcc ccgagcccgt gaccgtgagc 540
tggaactccg gcgccctgac atccggcgtg cacacattcc ccgccgtgct gcagtccagc 600
ggcctgtact ccctgagctc cgtggtgaca gtgccctcca gctccctggg cacccagacc 660
tacatctgca acgtgaacca caagcctagc aacacaaagg tggacaagag ggtggagccc 720
aagagctgcg acaagacaca cacctgccct ccctgtcctg cccctgagct gctgggcgga 780
ccttccgtgt tcctgttccc ccctaagccc aaggacacac tgatgatctc cagaacaccc 840
gaggtgacat gtgtggtggt ggatgtgagc cacgaggacc ccgaggtgaa gttcaactgg 900
tacgtggacg gcgtggaggt gcacaacgcc aagacaaagc ctcgggagga gcagtacaac 960
tccacataca gagtggtgtc cgtgctgacc gtgctgcacc aggattggct gaacggcaag 1020
gagtacaagt gcaaggtgag caacaaggcc ctgcccgccc ctatcgagaa gaccatctcc 1080
aaggccaagg gccagcccag ggagccccag gtttacacac tgccccccag cagagatgag 1140
ctgaccaaga accaggtgtc cctgacctgc ctggtgaagg gcttctaccc ctccgatatt 1200
gccgtggagt gggagagcaa cggccagccc gagaacaact acaagaccac accccccgtg 1260
ctggatagcg atggcagctt cttcctgtac agcaagctga ccgtggataa gtccagatgg 1320
cagcagggca acgtgttcag ctgttccgtg atgcacgagg ccctgcacaa ccactacaca 1380
cagaagagcc tgtccctgag ccctggcaag tga 1413
<210> 12
<211> 717
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
gccaccatgg acatgagggt gcctgcccag ctgctgggcc tgctgctgct gtggctgagc 60
ggcgctagat gcgatattca gatgacacag tcccctagca gcctgagcgc cagcgtgggc 120
gatagagtga ccatcacatg cagggccagc cagggcatct ccagctggct ggcctggtac 180
cagcagaagc ctgagaaggc ccctaagtcc ctgatctacg ccgcctccag cctgcagagc 240
ggcgtgccta gcaggttctc cggcagcggc agcggcacag atttcaccct gacaatcagc 300
tccctgcagc ccgaggactt cgccacctac tactgccagc agtacaacat ctacccctac 360
acattcggcc agggcaccaa gctggagatc aagaggacag tggccgcccc cagcgtgttc 420
atcttccctc ctagcgacga gcagctgaag agcggcacag cctccgtggt gtgtctgctg 480
aacaacttct accctcggga ggccaaggtg cagtggaagg tggacaacgc cctgcagtcc 540
ggcaactccc aggagagcgt gaccgagcag gatagcaagg actccaccta ctccctgagc 600
tccacactga cactgtccaa ggccgactac gagaagcaca aggtgtacgc ctgcgaggtg 660
acccaccagg gcctgtccag ccccgtgacc aagagcttca acagaggcga gtgctga 717
Claims (15)
1. A method of making an anti-IL-12 and/or IL-23 monoclonal antibody or antigen-binding fragment thereof comprising expressing said monoclonal antibody or said antigen-binding fragment using a DHFR knockout or GS knockout CHO cell, said monoclonal antibody or said antigen-binding fragment comprising a heavy chain variable region comprising VH-CDR1, VH-CDR2 and VH-CDR3 having the amino acid sequences shown in SEQ ID No. 1, SEQ ID No.2 and SEQ ID No. 3, respectively; the light chain variable region comprises VL-CDR1, VL-CDR2 and VL-CDR3 which have the amino acid sequences shown in SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6, respectively.
2. The method of claim 1, wherein the anti-IL-12 and/or IL-23 monoclonal antibody or antigen-binding fragment thereof comprises the heavy chain variable region of SEQ ID No. 7 and the light chain variable region of SEQ ID No. 8.
3. The method of claim 2, wherein the monoclonal antibody is an ubsunno monoclonal antibody.
4. A method according to any one of claims 1-3, the method comprising the steps of:
a) cloning the coding sequence of the monoclonal antibody into an expression vector to obtain a recombinant expression vector, wherein the expression vector preferably contains a selection marker gene, and more preferably the selection marker gene is a DHFR gene or a GS gene;
b) transferring the recombinant expression vector obtained in the step a) into a CHO cell with a DHFR gene knockout or a CHO cell with a GS gene knockout to obtain a CHO cell modified by genetic engineering;
c) culturing the genetically engineered CHO cell obtained in step b), and selecting a monoclonal cell strain expressing the antibody;
d) culturing the monoclonal cell strain expressing the antibody obtained in the step c), harvesting a cell culture solution containing the antibody, and separating and purifying to obtain the monoclonal antibody.
5. The method of any one of claims 1-4, wherein the DHFR gene knockout CHO cell is a CHO-DG44 cell.
7. An anti-IL-12 and/or IL-23 monoclonal antibody or antigen-binding fragment thereof prepared by the method of any one of claims 1-6.
8. A pharmaceutical composition comprising the monoclonal antibody produced by the method of any one of claims 1-6, sucrose, L-histidine hydrochloride monohydrate, and polysorbate 80.
9. The pharmaceutical composition of claim 8, comprising the monoclonal antibody 90 + 9mg/mL, sucrose 76 + 7.6mg/mL, L-histidine 0.5 + 0.3mg/mL, L-histidine hydrochloride monohydrate 1 + 0.5mg/mL, and polysorbate 800.04 + 0.004 mg/mL.
10. The pharmaceutical composition of claim 9, comprising the monoclonal antibody 90mg/mL, sucrose 76mg/mL, L-histidine 0.636mg/mL, L-histidine hydrochloride monohydrate 1.237mg/mL, and polysorbate 800.04 mg/mL.
11. A pharmaceutical composition comprising the monoclonal antibody prepared by the method of any one of claims 1-6, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, EDTA disodium salt dihydrate, and L-methionine.
12. The pharmaceutical composition of claim 11, comprising said monoclonal antibody 5 + 0.5mg/mL, L-histidine 0.77 + 0.077mg/mL, L-histidine hydrochloride monohydrate 1.03 + 0.10mg/mL, polysorbate 800.4 + 0.04mg/mL, sucrose 85 + 8.5mg/mL, EDTA disodium salt dihydrate 0.02 + 0.002mg/mL, and L-methionine 0.4 + 0.04 mg/mL.
13. The pharmaceutical composition of claim 12, comprising 5mg/mL of the monoclonal antibody, 0.77mg/mL of L-histidine, 1.03mg/mL of L-histidine hydrochloride monohydrate, 800.4 mg/mL of polysorbate, 85mg/mL of sucrose, 0.02mg/mL of EDTA disodium salt dihydrate, and 0.4mg/mL of L-methionine.
14. Use of an anti-IL-12 and/or IL-23 monoclonal antibody or antigen-binding fragment prepared by the method of any one of claims 1-6, or the pharmaceutical composition of any one of claims 8-13, in the manufacture of a medicament for the treatment of an IL-12 and/or IL-23 associated disease or disorder.
15. The use according to claim 14, the disease or disorder is selected from plaque psoriasis, psoriatic arthritis, crohn's disease, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, sarcoidosis, central spine arthritis, and ankylosing spondylitis; preferably, the disease or disorder is selected from plaque psoriasis, psoriatic arthritis and crohn's disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110174184 | 2021-02-09 | ||
CN2021101741843 | 2021-02-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114395041A true CN114395041A (en) | 2022-04-26 |
CN114395041B CN114395041B (en) | 2023-12-01 |
Family
ID=81232608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210109484.8A Active CN114395041B (en) | 2021-02-09 | 2022-01-29 | Method for preparing anti-IL-12 and/or IL-23 monoclonal antibody |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114395041B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024092203A1 (en) * | 2022-10-28 | 2024-05-02 | Amgen Inc. | Compositions of anti-interleukin 12/interleukin 23 antibody |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100021911A1 (en) * | 2008-07-23 | 2010-01-28 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Production host cell lines |
CN102876684A (en) * | 2012-09-17 | 2013-01-16 | 青岛康立泰药业有限公司 | Coding gene, eukaryotic host cell and expression method of human interleukin-12 |
WO2020183418A1 (en) * | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
-
2022
- 2022-01-29 CN CN202210109484.8A patent/CN114395041B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100021911A1 (en) * | 2008-07-23 | 2010-01-28 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Production host cell lines |
CN102876684A (en) * | 2012-09-17 | 2013-01-16 | 青岛康立泰药业有限公司 | Coding gene, eukaryotic host cell and expression method of human interleukin-12 |
WO2020183418A1 (en) * | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
Non-Patent Citations (2)
Title |
---|
JIANWEI ZHU等: "Mammalian cell protein expression for biopharmaceutical production", BIOTECHNOLOGY ADVANCES * |
杨林等: "细胞因子对类风湿性关节炎骨平衡的调节作用", 生命科学 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024092203A1 (en) * | 2022-10-28 | 2024-05-02 | Amgen Inc. | Compositions of anti-interleukin 12/interleukin 23 antibody |
Also Published As
Publication number | Publication date |
---|---|
CN114395041B (en) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI791894B (en) | Novel interleukin 2 and use thereof | |
JP2021516996A (en) | Biologically related orthogonal cytokine / receptor pair | |
CN112566698A (en) | T cell receptor and engineered cells expressing the same | |
WO2021185362A1 (en) | Interleukin-2 mutant and use thereof | |
MXPA04005190A (en) | Cell culture process. | |
JP2011518790A (en) | Method for producing a polyclonal protein | |
RU2716977C2 (en) | Novel selective vectors and methods for selecting eukaryotic host cells | |
KR20210102194A (en) | Implantable devices and related methods for cell therapy | |
EP3894549B1 (en) | Mutated piggybac transposase | |
CN114395041B (en) | Method for preparing anti-IL-12 and/or IL-23 monoclonal antibody | |
JP2012525826A (en) | CHO / CERT cell line | |
CN109867725B (en) | PD-1-Fc fusion protein and preparation method and application thereof | |
CN114349869B (en) | Bispecific NK cell agonist, preparation method and application | |
CN111378046A (en) | Immune effector cell conversion receptor | |
CN112458149A (en) | Method for detecting activation degree of antibody drug on T cells by taking CD3 as target | |
CN112442504B (en) | Preparation method of recombinant grass carp interleukin-12 active protein | |
KR101452286B1 (en) | Method for culturing cell expressing gdf5 as single clone in serum free medium with mtx and zeocin | |
KR101550677B1 (en) | Highly efficient production methods of fusion proteins for antibody treatment using catechin | |
CN113981027A (en) | Method for producing therapeutic proteins | |
WO2023150649A2 (en) | Synthetic degrader system for targeted protein degradation | |
CN117003851A (en) | Interleukin-2 mutein | |
CN113308491A (en) | Recombinant plasmid and recombinant cell for co-expressing NFAT and human DNAM-1 protein, and construction method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |